Cassava Sciences SAVA recently suffered yet another setback, which raises concern regarding its prospects. Last week, the company announced that the phase III study REFOCUS-ALZ on lead pipeline ...

Cassava Sciences (NASDAQ:SAVA) traded higher in the premarket on Tuesday after the Alzheimer’s drug developer received its only buy rating on Wall Street as H.C. Wainwright upgraded the stock, citing ...

Cassava Sciences (NASDAQ:SAVA) stock is falling Monday after the company shared an update on its Phase 3 trial for a treatment for Alzheimer's disease that has been widely followed by the market.

Cassava Sciences (SAVA) has gone down about 30% since November, the last time I covered it (this article has not been published). The reason for the decline could have been attributed to the data drop ...

Cassava says failed trial results have impacted its second Phase 3 trial, ReFocus-ALZ; decides to discontinue ReFocus-ALZ Cassava says it will continue to review the data and evaluate the next steps.

In March, pharmaceutical company Cassava Sciences made headlines for a report by the Food and Drug Administration (FDA) that cast doubt on the positive trial results of its novel Alzheimer’s drug, ...